Biotech Investor Roundup: September 2024

The biotech sector has seen significant investment activity in September 2024. Here's a detailed look at the key highlights:

Major Funding Rounds

1. Neurocyte Therapeutics secured a $210 million Series C round on September 5, 2024, led by Fidelity Management and Research Company. This funding will advance their gene therapy platform for neurodegenerative diseases, including a phase 2 trial for their lead candidate targeting Alzheimer's disease.

2. Vicebio raised ￡75 million ($92 million) in a Series B round on September 23, 2024, led by TCGX. The company will use the funds to accelerate the development of their Molecular Clamp technology for next-generation respiratory virus vaccines, with plans to initiate phase 1 trials for their universal influenza vaccine in Q1 2025.

3. Quantum Biologics closed a $180 million Series D financing on September 15, 2024, co-led by Perceptive Advisors and RA Capital Management. This funding will support phase 3 trials of their quantum computing-designed antibodies for autoimmune diseases, with a focus on their lead candidate for rheumatoid arthritis.

4. GeneFlow Therapeutics announced a $135 million Series B on September 8, 2024, led by ARCH Venture Partners. The company plans to advance its RNA-based gene therapy platform, including initiating a phase 1/2 trial for their lead candidate targeting Duchenne muscular dystrophy.

5. Synaptica Pharma secured $95 million in Series A funding on September 19, 2024, led by Andreessen Horowitz's bio fund. This investment will fuel the development of their AI-driven neuroscience drug discovery platform, with a focus on identifying novel targets for neurodegenerative diseases.

6. Immunoforge Biotech raised $88 million in Series C funding on September 12, 2024, led by OrbiMed. The company will use the funds to progress its immuno-oncology pipeline, including a phase 2 trial for their bispecific antibody targeting solid tumors.

7. Cellectis Therapeutics obtained $120 million through a private placement on September 25, 2024, with participation from Pfizer Ventures and Bayer. This funding will support their CRISPR-based cell therapy programs, including a phase 1 trial for their allogeneic CAR-T therapy in acute myeloid leukemia.

8. Microbiome Dynamics closed a $75 million Series B on September 3, 2024, led by Flagship Pioneering. The company will advance its microbiome-based therapeutics for metabolic diseases, with plans to initiate a phase 2 trial for their lead candidate in type 2 diabetes.

Emerging Players

1. Invizius, an Edinburgh-based biotech developing treatments for dialysis patients, raised ￡950,000 ($1.17 million) on September 23, 2024, from existing investors including Scottish Enterprise. This seed extension will fund GMP manufacturing of their lead candidate, H-Guard, in preparation for first-in-human trials.

2. NanoVax Therapeutics secured $25 million in seed funding on September 7, 2024, led by Khosla Ventures. The company's nanoparticle-based vaccine delivery technology aims to improve vaccine stability and efficacy, with initial focus on developing a universal coronavirus vaccine.

3. Epigenix Biotech raised $18 million in Series A funding on September 14, 2024, led by Sofinnova Partners. They will use the funds to advance their epigenetic therapies for rare diseases, including preclinical development of their lead candidate for Angelman syndrome.

4. BioCircuit Labs closed a $22 million Series A on September 10, 2024, led by NEA. The company's bioelectronic medicine platform targets chronic pain conditions, with plans to initiate a pilot study for their implantable device in chronic lower back pain.

5. Proteomics AI obtained $15 million in seed funding on September 21, 2024, from a16z bio + health. Their AI-driven protein analysis platform aims to accelerate drug discovery by identifying novel protein-protein interactions and drug targets.

6. Neuro-Optics secured $20 million in Series A funding on September 18, 2024, led by Versant Ventures. The company is developing a novel optogenetic approach to treating retinal diseases, with plans to file an IND for their lead candidate in retinitis pigmentosa by mid-2025.

7. Genomic Frontiers raised $12 million in seed funding on September 9, 2024, led by F-Prime Capital. They are developing CRISPR-based diagnostic tools for rapid, point-of-care detection of infectious diseases and cancer biomarkers.

8. Immuno-Logic Therapeutics closed a $28 million Series A on September 28, 2024, led by Novo Ventures. The company uses AI to design novel immunotherapies, with a lead candidate targeting solid tumors expected to enter preclinical development in Q1 2025.

Venture Capital Activity

1. ARCH Venture Partners raised a $3 billion fund, announced on September 27, 2024. Co-founder Robert Nelsen stated they remain in "taking lots of risk mode," focusing on cutting-edge science and artificial intelligence applications in drug discovery. The fund plans to invest in 25-30 companies over the next 3-4 years.

2. Sofinnova Partners closed a $600 million crossover fund on September 20, 2024, focusing on late-stage biotech investments. The fund aims to bridge the gap between private and public markets, targeting companies with phase 2 or later assets.

3. OrbiMed announced a new $1.5 billion healthcare fund on September 15, 2024, with a significant allocation to biotech startups. The fund will invest globally, with a particular focus on precision medicine and digital health companies.

4. Versant Ventures raised a $750 million fund on September 8, 2024, targeting early-stage biotech companies. The firm plans to continue its company creation efforts, with a focus on novel modalities and platform technologies.

5. RA Capital Management launched an $800 million "Nexus" fund on September 22, 2024, focused on the convergence of biotech and tech sectors. The fund will invest in companies leveraging AI, machine learning, and data science for drug discovery and development.

6. Third Rock Ventures closed a $1.2 billion fund on September 12, 2024, dedicated to creating and building innovative healthcare companies. The firm plans to launch 10-12 new companies from this fund over the next several years.

7. Flagship Pioneering announced a $1.1 billion Origination Fund on September 5, 2024, to fuel its unique company creation model. The fund will focus on developing groundbreaking platforms in areas such as cellular agriculture, programmable medicines, and synthetic biology.

8. Atlas Venture raised a $450 million fund on September 30, 2024, focused on seed and Series A investments in life sciences companies. The firm plans to continue its hands-on approach to company building, with a particular interest in novel therapeutic modalities and computational biology.

This flurry of activity demonstrates continued investor confidence in biotech innovation, particularly in areas like precision medicine, novel vaccine technologies, and AI-driven drug discovery. The sector's resilience is evident in the face of broader market challenges, with selective investments in promising technologies and therapeutic approaches.

Don't forget to subscribe for future updates!

Yasir Hassan

The Biotech Investor